SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-094622
Filing Date
2024-11-05
Accepted
2024-11-05 17:05:07
Documents
15
Period of Report
2024-11-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea022011301-8k_actinium.htm   iXBRL 8-K 24826
2 PRESS RELEASE, DATED NOVEMBER 4, 2024. ea022011301ex99-1_actinium.htm EX-99.1 10878
3 GRAPHIC image_001.jpg GRAPHIC 48316
  Complete submission text file 0001213900-24-094622.txt   281625

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE atnm-20241101.xsd EX-101.SCH 3060
5 XBRL LABEL FILE atnm-20241101_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE atnm-20241101_pre.xml EX-101.PRE 22389
17 EXTRACTED XBRL INSTANCE DOCUMENT ea022011301-8k_actinium_htm.xml XML 3688
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 241428446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)